Alvotech (NASDAQ:ALVO) Stock Moved Up to Hold by Wall Street Zen

Key Points

• Wall Street Zen upgraded Alvotech from “sell” to “hold.” Overall analyst sentiment is mixed, with MarketBeat reporting an average “hold” rating and an $8.40 consensus price target.
• Alvotech shares fell to $4.19 in Friday trading, down $0.48.
• The company reported a quarterly loss of $0.03 per share, in line with consensus, but revenue of $111.6 million came in below analysts’ expectations.

Alvotech (NASDAQ:ALVO - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Sunday, Wall Street Zen reports.

ALVO has been the topic of several other research reports. Zacks Research downgraded shares of Alvotech from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 20th. Weiss Ratings raised shares of Alvotech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, November 4th. Evercore began coverage on shares of Alvotech in a research note on Friday, August 14th. They set an "outperform" rating for the company. Bank of America assumed coverage on shares of Alvotech in a report on Monday, August 24th. They set a "buy" rating and a $7.00 price objective on the stock. Finally, UBS Group set a $8.00 target price on Alvotech in a research report on Wednesday, September 16th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $8.40.

Alvotech Price Performance

NASDAQ ALVO traded down $0.48 during trading on Friday, hitting $4.19. The company's stock had a trading volume of 2,091,332 shares, compared to its average volume of 947,613. The company has a market cap of $1.26 billion, a PE ratio of -5.11 and a beta of 0.24. The business's 50 day simple moving average is $5.23 and its 200-day simple moving average is $4.20. Alvotech has a fifty-two week low of $2.94 and a fifty-two week high of $6.53.

Alvotech (NASDAQ:ALVO - Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.03). The business had revenue of $111.60 million for the quarter, compared to analysts' expectations of $123.45 million. Analysts expect that Alvotech will post -0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Alvotech

Institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in Alvotech during the third quarter valued at $2,326,000. State Street Corp acquired a new position in shares of Alvotech in the third quarter worth about $594,000. Royce & Associates LP acquired a new position in shares of Alvotech in the third quarter worth about $3,817,000. Commonwealth Equity Services LLC purchased a new stake in shares of Alvotech during the 3rd quarter worth about $69,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Alvotech during the 3rd quarter valued at about $100,000.

Latest Alvotech News

Investors following ALVO have been watching these news items:

• Positive Sentiment: Alvotech forecast 2026 revenue of $650 million–$700 million, broadly around or above the $652.5 million consensus at the midpoint, and EBITDA of $180 million–$220 million. Management said it expects the fourth quarter to be the strongest in company history. Article: Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA
• Neutral Sentiment: The earnings call highlighted growth opportunities alongside business risks; the available article summary did not specify further details. Article: Alvotech Earnings Call Highlights Growth and Risks
• Negative Sentiment: Q3 revenue of $111.6 million fell short of the $125.2 million analyst estimate. Alvotech posted a loss of $0.03 per share; while that beat one reported consensus estimate of a $0.04 loss, it missed Zacks’ estimate of a $0.01 loss. The revenue miss and mixed earnings comparisons could pressure the shares. Article: Alvotech Reports Q3 Loss, Lags Revenue Estimates

About Alvotech

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.